Loring Wolcott & Coolidge Fiduciary Advisors’s Biogen BIIB Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Hold	6,193	–	–	0.01%	153
2026 Q1	$1.07M	Hold	6,193	–	–	0.01%	159
2025 Q4	$1.08M	Hold	6,193	–	–	0.01%	159
2025 Q3	$929K	Hold	6,193	–	–	0.01%	180
2025 Q2	$778K	Hold	6,193	–	–	0.01%	173
2025 Q1	$732K	Sell	6,193 -286	-4%	-$40.9K	0.01%	177
2024 Q4	$964K	Hold	6,479	–	–	0.01%	168
2024 Q3	$1.19M	Sell	6,479 -26	-0.4%	-$5.44K	0.01%	154
2024 Q2	$1.46M	Buy	6,505 +26	+0.4%	+$5.65K	0.01%	132
2024 Q1	$1.26M	Hold	6,479	–	–	0.01%	135
2023 Q4	$1.6M	Sell	6,479 -230	-3%	-$56.5K	0.02%	126
2023 Q3	$1.62M	Hold	6,709	–	–	0.02%	122
2023 Q2	$1.91M	Sell	6,709 -175	-3%	-$52.1K	0.02%	117
2023 Q1	$1.91M	Sell	6,884 -200	-3%	-$55.3K	0.02%	114
2022 Q4	$1.96M	Sell	7,084 -175	-2%	-$49.4K	0.02%	110
2022 Q3	$1.94M	Sell	7,259 -26	-0.4%	-$5.52K	0.03%	111
2022 Q2	$1.49M	Buy	7,285 +26	+0.4%	+$5.32K	0.02%	130
2022 Q1	$1.53M	Hold	7,259	–	–	0.02%	137
2021 Q4	$1.74M	Sell	7,259 -400	-5%	-$103K	0.02%	136
2021 Q3	$2.17M	Sell	7,659 -75	-1%	-$24.6K	0.02%	117
2021 Q2	$2.68M	Sell	7,734 -468	-6%	-$142K	0.03%	111
2021 Q1	$2.29M	Sell	8,202 -86	-1%	-$23.2K	0.03%	112
2020 Q4	$2.03M	Buy	8,288 +4	+0%	+$1.03K	0.02%	114
2020 Q3	$2.35M	Hold	8,284	–	–	0.03%	104
2020 Q2	$2.22M	Hold	8,284	–	–	0.03%	108
2020 Q1	$2.62M	Hold	8,284	–	–	0.04%	92
2019 Q4	$2.46M	Sell	8,284 -11	-0.1%	-$3.05K	0.03%	106
2019 Q3	$1.93M	Sell	8,295 -50	-0.6%	-$11.6K	0.03%	117
2019 Q2	$1.95M	Sell	8,345 -28	-0.3%	-$6.46K	0.03%	116
2019 Q1	$1.98M	Sell	8,373 -54	-0.6%	-$17K	0.03%	119
2018 Q4	$2.54M	Buy	8,427 +54	+0.6%	+$17.2K	0.05%	106
2018 Q3	$2.96M	Sell	8,373 -100	-1%	-$34.4K	0.05%	106
2018 Q2	$2.46M	Hold	8,473	–	–	0.04%	109
2018 Q1	$2.32M	Sell	8,473 -50	-0.6%	-$15.5K	0.04%	117
2017 Q4	$2.71M	Hold	8,523	–	–	0.05%	111
2017 Q3	$2.67M	Buy	8,523 +11	+0.1%	+$3.26K	0.05%	110
2017 Q2	$2.46M	Buy	8,512 +28	+0.3%	+$7.4K	0.05%	108
2017 Q1	$2.32M	Buy	8,484 +700	+9%	+$198K	0.05%	113
2016 Q4	$2.21M	Hold	7,784	–	–	0.05%	112
2016 Q3	$2.44M	Buy	7,784 +50	+0.6%	+$14.8K	0.06%	113
2016 Q2	$1.87M	Hold	7,734	–	–	0.04%	119
2016 Q1	$2.01M	Sell	7,734 -20	-0.3%	-$5.28K	0.05%	116
2015 Q4	$2.38M	Sell	7,754 -500	-6%	-$144K	0.06%	114
2015 Q3	$3.33M	Hold	8,254	–	–	0.09%	101
2015 Q2	$3.33M	Hold	8,254	–	–	0.09%	101
2015 Q1	$3.48M	Sell	8,254 -125	-1%	-$49.3K	0.09%	99
2014 Q4	$2.84M	Buy	8,379 +250	+3%	+$80.9K	0.07%	103
2014 Q3	$2.69M	Hold	8,129	–	–	0.07%	105
2014 Q2	$2.56M	Sell	8,129 -85	-1%	-$25.6K	0.07%	105
2014 Q1	$2.51M	Sell	8,214 -252	-3%	-$80K	0.07%	109
2013 Q4	$2.37M	Buy	8,466 +167	+2%	+$43.2K	0.07%	109
2013 Q3	$2M	Hold	8,299	–	–	0.06%	113
2013 Q2	$1.79M	Buy	+8,299	New	+$1.77M	0.06%	121

Other funds holding BIIB

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's BIIB Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors held its Biogen (BIIB) position steady in Q2 2026 at 6,193 shares worth $1.34M. The position accounts for 0.01% of the portfolio, ranked #153.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.48M in Q1 2015. 524 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Loring Wolcott & Coolidge Fiduciary Advisors held 6,193 shares of Biogen worth $1.34M as of Q2 2026.
Loring Wolcott & Coolidge Fiduciary Advisors left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #153 holding.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
Loring Wolcott & Coolidge Fiduciary Advisors's Biogen position peaked at $3.48M in Q1 2015.
524 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.